Accumulation of Ordered Ceramide-Cholesterol Domains in Farber Disease Fibroblasts
Open Access
- 12 July 2013
- book chapter
- Published by Springer Nature
- Vol. 12, 71-77
Abstract
Farber disease is an inherited metabolic disorder caused by mutations in the acid ceramidase gene, which leads to ceramide accumulation in lysosomes. Farber disease patients display a wide variety of symptoms with most patients eventually displaying signs of nervous system dysfunction. We now present a novel tool that could potentially be used to distinguish between the milder and more severe forms of the disease, namely, an antibody that recognizes a mixed monolayer or bilayer of cholesterol:C16-ceramide, but does not recognize either ceramide or cholesterol by themselves. This antibody has previously been used to detect cholesterol:C16-ceramide domains in a variety of cultured cells. We demonstrate that levels of cholesterol:C16-ceramide domains are significantly elevated in fibroblasts from types 4 and 7 Farber disease patients, and that levels of the domains can be modulated by either reducing ceramide or cholesterol levels. Moreover, these domains are located in membranes of the endomembrane system, and also in two unexpected locations, namely, the mitochondria and the plasma membrane. This study suggests that the ceramide that accumulates in severe forms of Farber disease cells is sequestered to distinct membrane subdomains, which may explain some of the cellular pathology observed in this devastating lysosomal storage disease.Keywords
This publication has 29 references indexed in Scilit:
- The BCL-2 Protein BAK Is Required for Long-chain Ceramide Generation during ApoptosisJournal of Biological Chemistry, 2010
- Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cellsProceedings of the National Academy of Sciences, 2010
- Lipid Rafts As a Membrane-Organizing PrincipleScience, 2010
- Principles of bioactive lipid signalling: lessons from sphingolipidsNature Reviews Molecular Cell Biology, 2008
- Farber disease: clinical presentation, pathogenesis and a new approach to treatmentPediatric Rheumatology, 2007
- Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factorsProceedings of the National Academy of Sciences, 2003
- A family with combined Farber and Sandhoff, isolated Sandhoff and isolated fetal Farber disease: postnatal exclusion and prenatal diagnosis of Farber disease using lipid loading tests on intact cultured cellsEuropean Journal of Pediatrics, 1995
- The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber diseaseFEBS Letters, 1993
- Farber lipogranulomatosis: An unusual presentation in a black childPediatric Neurology, 1986
- Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblastsThe Journal of Pediatrics, 1976